I believe the validating moment will be upon FDA acceptance of the NDA filing. Until then, I don’t believe IPCI has validated themselves to the market enough yet to generate a comparable valuation (the $ 3.00 - $ 4.50 range based on comps is again at that timeframe). It’s hard to compare until then since that is pretty concrete evidence the market would look for as to where they are in terms of establishing a new timeframe to market. While ELTP and PTIE have both already had that confirmation and the market acknowledged that catalyst, IPCI is still a couple months away. If at that time we are still lingering far below comps in terms of valuation, I too will think I must be missing something. Until then, it is the steady as she goes waiting game it has been for some time now.